Statistics for A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors
Total visits
| views | |
|---|---|
| A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors | 187 |
Total visits per month
| views | |
|---|---|
| May 2024 | 0 |
| June 2024 | 0 |
| July 2024 | 0 |
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
File Visits
| views | |
|---|---|
| 10637_2019_Article_768.pdf | 162 |
Top country views
| views | |
|---|---|
| United States | 148 |
| Germany | 9 |
| Ukraine | 4 |
| United Kingdom | 2 |
| Vietnam | 2 |
| Belgium | 1 |
| Canada | 1 |
| China | 1 |
| France | 1 |
| Malaysia | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 48 |
| Fairfield | 24 |
| San Francisco | 15 |
| Houston | 11 |
| Cambridge | 8 |
| Gunzenhausen | 5 |
| Jacksonville | 5 |
| Kiev | 4 |
| Kiez | 4 |
| Kansas City | 3 |
| Dong Ket | 2 |
| Seattle | 2 |
| Ann Arbor | 1 |
| Aulnay-sous-bois | 1 |
| Brooklyn | 1 |
| Irvine | 1 |
| Scottsdale | 1 |
| Seremban | 1 |
| Toronto | 1 |
| Washington | 1 |
| Zaventem | 1 |